Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupHKSE:02005 86 Operating Margin % is 15.56% as of Dec. 2025, which is 36% below its 10-year median of 24.24. GuruFocus rates HKSE:02005 with a GF Score™ of 86/100 and a GF Value™ of HK$3.04 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 960 Drug Manufacturers companies, SSY Group ranks better than 67.71% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. SSY Group's Operating Income for the
six
months ended in Dec. 2025 was HK$314 Mil. SSY Group's Revenue for the
six
months ended in Dec. 2025 was HK$2,018 Mil. Therefore, SSY Group's Operating Margin % for the quarter that ended in Dec. 2025 was 15.56%.
The historical rank and industry rank for SSY Group's Operating Margin % or its related term are showing as below:
HKSE:02005'
s Operating Margin % Range Over the Past 10 Years
Min: 14.02 Med: 24.24 Max: 27.73
Current: 14.02
HKSE:02005's Operating Margin % is ranked better than 67.71% of 960
companies
in the Drug Manufacturers industry
Industry Median: 7.51
vs HKSE:02005: 14.02
SSY Group's 5-Year Average Operating Margin % Growth Rate was -0.70% per year.
SSY Group's Operating Income for the
six
months ended in Dec. 2025 was HK$314 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was HK$584 Mil.
SSY Group (HKSE:02005) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
SSY Group Operating Margin % Related Terms
SSY Group Operating Margin % Historical Data
* Premium members only.
The historical data trend for SSY Group's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's Operating Margin % distribution charts can be found below:
* The bar in red indicates where SSY Group's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
SSY Group's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (HKSE:02005) has a Operating Margin % of 15.56% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on SSY Group and its competitors. This is 36% below median its historical median of 24.24. Over the past decade, SSY Group's Operating Margin % has ranged from 14.02 to 27.73. According to the industry distribution chart, SSY Group ranks #310 out of 960 companies in the Drug Manufacturers industry, placing it in the top 32.3%.
Is SSY Group's Operating Margin % too high?
SSY Group's current Operating Margin % of 15.56% is 36% below median its 10-year median of 24.24. Over the past 10 years, this metric has ranged from a low of 14.02 to a high of 27.73. The Drug Manufacturers industry median Operating Margin % is 7.51. SSY Group's value of 15.56% is 107.2% above this industry median. Based on the distribution chart, SSY Group ranks #310 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, SSY Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SSY Group's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #310 out of 960 companies for Operating Margin %. This puts SSY Group in the upper half of its industry. The industry median Operating Margin % is 7.51. SSY Group's value of 15.56% is 107.2% above this benchmark. Historically, SSY Group's own Operating Margin % has ranged from 14.02 to 27.73 over the past decade. While the company's 10-year median is 24.24 vs. the industry median of 7.51, SSY Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.51, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current Operating Margin % of 15.56% is 107.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current Operating Margin % is 15.56%, which is 36% below median its own 10-year median of 24.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
Based on GuruFocus' analysis, SSY Group (HKSE:02005) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.04, compared to a current price of HK$2.40 — trading 21.1% below its estimated fair value. The current Operating Margin % is 15.56%, which is 36% below median its 10-year median of 24.24 and 107.2% above the Drug Manufacturers industry median of 7.51. SSY Group's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For SSY Group (HKSE:02005), the current Operating Margin % is 15.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (HKSE:02005) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of HK$2.40 is trading 21.1% below its estimated GF Value™ of HK$3.04.
GuruFocus considers SSY Group to be Modestly Undervalued.
Key valuation signals for HKSE:02005:
Operating Margin %: 15.56% (36% below median its 10-year median of 24.24)
GF Value™: HK$3.04 vs. price of HK$2.40 (21.1% below fair value)
Industry Position: 107.2% above the Drug Manufacturers median (#310 of 960)
No single metric tells the full story. See the HKSE:02005 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
86GF Score
Get the complete analysis for HKSE:02005
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02005 has been successfully added to your 
